
  
    
      
        Background_NNP
        It_PRP has_VBZ been_VBN suggested_VBN that_IN solid_JJ tumours_NNS can_MD not_RB grow_VB
        beyond_IN 60_CD -_: 80_CD cells_NNS without_IN inducing_VBG the_DT formation_NN of_IN new_JJ
        blood_NN vessels_NNS :_: tumour_NN angiogenesis_NNS [_NN 1_CD ]_NN ._. This_DT blood_NN
        vessel_NN formation_NN requires_VBZ proliferation_NN of_IN endothelial_NN
        cells_NNS ,_, cell_NN migration_NN and_CC the_DT lysis_NNS of_IN the_DT different_JJ
        components_NNS of_IN the_DT matrix_NN (_( collagen_NN ,_, elastin_NN ,_, fibronectin_NN )_)
        by_IN several_JJ proteases_NNS ._. One_CD of_IN great_JJ importance_NN ,_, urokinase_NN
        (_( uPA_NN )_) and_CC its_PRP$ high_JJ affinity_NN receptor_NN ,_, the_DT GPI-anchored_NNP
        membrane_NN CD_NNP 87_CD (_( uPAR_NN )_) ,_, is_VBZ critical_JJ in_IN tumour_NN progression_NN and_CC
        its_PRP$ level_NN of_IN expression_NN is_VBZ correlated_JJ with_IN poor_JJ prognosis_NN
        of_IN various_JJ cancers_NNS such_JJ as_IN prostate_NN [_NN 2_CD ]_NN ,_, breast_NN [_NN 3_CD ]_NN ,_,
        colon_NN [_NN 4_CD ]_NN ,_, ovarian_NN [_NN 5_CD ]_NN ,_, gastric_JJ [_NN 6_CD ]_NN ,_, brain_NN [_NN 7_CD ]_NN ,_,
        and_CC lung_NN cancer_NN [_NN 8_CD ]_NN ._. Urokinase_NNP (_( uPA_NN )_) and_CC its_PRP$ main_JJ
        product_NN plasmin_NN belong_VB to_TO the_DT very_RB early_JJ proteases_NNS [_NN 9_CD 10_CD
        11_CD ]_NN that_WDT activate_VBP the_DT metallo-protease_JJ (_( MMP_NNP )_) cascade_NN and_CC
        therefore_RB control_VB cell_NN motility_NN ,_, tissue_NN remodelling_VBG and_CC the_DT
        activation_NN of_IN various_JJ angiogenic_JJ factors_NNS (_( VEGF_NNP ,_, TGFβ_NNP )_) ._. Most_JJS
        of_IN these_DT proteases_NNS (_( e_SYM ._. g_SYM ._. uPA_NN )_) are_VBP localised_JJ at_IN the_DT tumour_NN
        site_NN through_IN receptors_NNS that_WDT are_VBP highly_RB expressed_VBN on_IN the_DT
        surface_NN of_IN activated_VBN endothelial_NN cells_NNS and_CC tumour_NN cells_NNS ._. A_DT
        high_JJ level_NN of_IN uPAR_NN at_IN the_DT invasive_JJ edge_NN of_IN the_DT tumour_NN
        concentrates_VBZ uPA_NN where_WRB neoangiogenesis_NNS occurs_VBZ [_NN 12_CD ]_NN ,_,
        generating_VBG the_DT full_JJ activation_NN of_IN the_DT MMP_NNP cascade_NN [_NN 13_CD ]_NN ._.
        Furthermore_RB ,_, various_JJ cellular_JJ migrations_NNS proceed_VBP upon_IN the_DT
        transient_JJ attachment_NN of_IN the_DT uPAR_NN to_TO matrix_NN components_NNS (_( e_SYM ._. g_SYM ._.
        vitronectin_NN )_) [_NN 14_CD ]_NN ,_, and_CC uPA_NN as_RB well_RB as_IN plasmin_NN activate_VBP
        angiogenic_JJ factors_NNS such_JJ as_IN VEGF_NNP ,_, HGF_NNP ,_, FGFs_NNP ,_, and_CC TGFβ_NNP [_NN 15_CD
        16_CD 17_CD ]_NN ._.
        The_DT inhibitors_NNS of_IN the_DT matrix_NN lysis_NNS can_MD be_VB divided_VBN in_IN two_CD
        categories_NNS :_: the_DT synthetic_JJ inhibitors_NNS and_CC the_DT endogenous_JJ
        ones_NNS ._. Most_JJS of_IN the_DT synthetic_JJ inhibitors_NNS are_VBP competitive_JJ
        inhibitors_NNS of_IN the_DT metallo-proteases_JJ ,_, mimicking_VBG the_DT
        substrate_NN of_IN the_DT enzymes_NNS (_( marismatat_NN and_CC derivatives_NNS )_) ._. The_DT
        endogenous_JJ inhibitors_NNS (_( e_SYM ._. g_SYM ._. endostatin_NN ,_, angiostatin_NN ,_,
        thrombospondin_NN )_) differ_VB in_IN their_PRP$ angiostatic_JJ activity_NN from_IN
        synthetic_JJ inhibitors_NNS ,_, since_IN they_PRP appear_VBP to_TO also_RB block_VB
        endothelial_NN cell_NN proliferation_NN and_CC /_NN or_CC migration_NN ._. In_IN this_DT
        paper_NN we_PRP described_VBD the_DT antitumour_NN effects_NNS of_IN a_DT hybrid_JJ
        protein_NN ,_, consisting_VBG of_IN the_DT Amino_NNP Terminal_NNP Fragment_NNP linked_VBD
        to_TO Bovine_NNP Pancreatic_NNP Trypsin_NNP Inhibitor_NNP (_( ATF-BPTI_NNP )_) ,_,
        delivered_VBN by_IN gene_NN therapy_NN with_IN adenoviral_NN vector_NN ._.
        ATF_NNP is_VBZ the_DT N-_NNP terminal_NN part_NN of_IN the_DT uPA_NN (_( residues_NNS 1_CD -_: 135_CD )_)
        that_IN binds_NNS to_TO the_DT uPA_NN receptor_NN (_( uPAR_NN )_) and_CC thus_RB inhibits_NNS the_DT
        formation_NN of_IN the_DT uPA-uPAR_JJ complex_NN ._. Systemic_NNP and_CC local_JJ
        delivery_NN of_IN an_DT adenovirus_JJ encoding_VBG ATF_NNP have_VBP been_VBN shown_VBN to_TO
        inhibit_VB the_DT growth_NN of_IN primary_JJ tumour_NN implants_NNS as_RB well_RB as_IN of_IN
        tumour_NN metastasis_NNS in_IN different_JJ animal_NN models_NNS [_NN 18_CD 19_CD ]_NN ._. In_IN
        the_DT ATF-BPTI_NNP chimeric_JJ protein_NN ,_, ATF_NNP has_VBZ two_CD functions_NNS (_( 1_LS )_)
        the_DT anti_NN uPA_NN effect_NN with_IN its_PRP$ known_VBN angiostatic_JJ activity_NN and_CC
        (_( 2_LS )_) delivery_NN of_IN BPTI_NNP at_IN the_DT tumour_NN site_NN due_JJ to_TO
        over-expression_JJ of_IN uPAR_NN on_IN tumour_NN and_CC endothelial_NN cells_NNS ._.
        The_DT ATF_NNP is_VBZ species_NNS specific_JJ between_IN the_DT human_JJ and_CC the_DT mouse_NN
        [_NN 20_CD ]_NN and_CC is_VBZ not_RB specific_JJ between_IN the_DT mouse_NN and_CC the_DT rat_NN ._.
        The_DT murinised_JJ version_NN of_IN ATF-BPTI_NNP differs_VBZ by_IN four_CD amino_JJ
        acids_NNS from_IN the_DT human_JJ version_NN It_PRP was_VBD shown_VBN to_TO bind_NN to_TO the_DT
        rat_NN receptor_NN and_CC to_TO inhibit_VB plasmin_NN activity_NN in_IN a_DT rat_NN model_NN
        [_NN 21_CD ]_NN ._. BPTI_NNP (_( commercialised_JJ as_IN aprotinin_NN )_) is_VBZ a_DT serine_NN
        protease_NN inhibitor_NN prepared_VBN from_IN bovine_JJ lung_NN tissue_NN which_WDT
        dose_NN dependently_RB inhibits_NNS human_JJ trypsin_NN ,_, plasmin_NN and_CC
        kallikrein_NN ._. Aprotinin_NNP acts_NNS in_IN a_DT number_NN of_IN interrelated_JJ ways_NNS
        to_TO provide_VB an_DT anti-fibrinolytic_JJ effect_NN ._. Thus_RB ,_, aprotinin_NN is_VBZ
        mainly_RB used_VBN in_IN the_DT clinic_NN as_IN anti-haemorrhagic_JJ agent_NN in_IN
        extracorporal_NN circulation_NN (_( valve_NN replacement_NN ,_, coronary_JJ
        by-pass_JJ )_) ,_, for_IN preventing_VBG postoperative_JJ haemorrhage_NN ,_, and_CC as_IN
        anti_NN protease_NN in_IN acute_JJ pancreatitis_NNS ._. BPTI_NNP has_VBZ been_VBN used_VBN
        systemically_RB in_IN a_DT few_JJ animal_NN tumour_NN models_NNS ,_, and_CC showed_VBD
        anti-tumour_JJ effects_NNS in_IN a_DT mouse_NN hepatoma_NN ,_, lung_NN carcinoma_NN ,_,
        and_CC mammary_JJ carcinoma_NN [_NN 22_CD 23_CD 24_CD ]_NN ,_, and_CC in_IN a_DT fibrosarcoma_NN
        of_IN the_DT hamster_NN [_NN 24_CD ]_NN ._. However_RB ,_, BPTI_NNP was_VBD not_RB further_RBR
        developed_VBN as_IN a_DT systemic_JJ anti_NN tumour_NN agent_NN probably_RB because_IN
        of_IN its_PRP$ anti_NN fibrinolytic_JJ property_NN that_WDT might_MD preclude_VB its_PRP$
        use_NN in_IN cancer_NN patients_NNS ._. Its_PRP$ linkage_NN to_TO ATF_NNP is_VBZ expected_VBN to_TO
        ameliorate_NN or_CC reduce_VB that_DT side_NN effect_NN ._.
        In_IN this_DT study_NN ,_, the_DT tumour_NN growth_NN inhibiting_VBG effect_NN of_IN
        ATF-BPTI_NNP gene_NN transfer_NN was_VBD investigated_VBN and_CC compared_VBN to_TO
        endostatin_NN and_CC ATF_NNP ._. The_DT adenoviral_NN vector_NN was_VBD administered_VBN
        intravenously_RB ,_, which_WDT leads_VBZ to_TO the_DT ATF-BPTI_NNP production_NN and_CC
        secretion_NN by_IN the_DT liver_NN ,_, or_CC by_IN intra_NN tumoral_NN injection_NN ._. In_IN
        the_DT latter_JJ case_NN ,_, the_DT protein_NN is_VBZ mostly_RB produced_VBN by_IN
        transduced_JJ tumour_NN cells_NNS ._. Two_CD transplantable_JJ rat_NN bronchial_NN
        carcinomas_NNS ,_, growing_VBG either_CC as_IN subcutaneous_JJ implants_NNS or_CC as_IN
        lung_NN metastasis_NNS were_VBD employed_VBN as_IN targets_NNS ._. Levels_NNP of_IN
        ATF-BPTI_NNP in_IN the_DT plasma_NN and_CC in_IN tissues_NNS were_VBD determined_VBN and_CC
        the_DT association_NN with_IN tumour_NN responses_NNS is_VBZ described_VBN ._.
      
      
        Methods_NNP
        
          Animals_NNS
          Pathogen-free_NNP inbred_JJ male_JJ Wag_NNP /_NN Rij_NNP and_CC Brown_NNP Norway_NNP
          rats_NNS ,_, weighing_VBG 300_CD to_TO 350_CD gr_NN were_VBD purchased_VBN from_IN Harlan_NNP ,_,
          The_DT Netherlands_NNP ._. All_DT animals_NNS were_VBD fed_VBN ad_NN libitum_NN with_IN
          laboratory_NN chow_NN and_CC water_NN and_CC were_VBD kept_VBN under_IN standard_JJ
          laboratory_NN conditions_NNS ._. For_IN assay_NN of_IN plasma_NN hEndostatin_NN ,_,
          and_CC mhATF-BPTI_JJ ,_, rats_NNS were_VBD anaesthetised_JJ with_IN isoflurane_NN
          and_CC bled_VBD by_IN tail_NN vein_NN puncture_NN and_CC the_DT blood_NN was_VBD
          collected_VBN in_IN EDTA_NNP containing_VBG tubes_NNS ._. All_DT animal_NN procedures_NNS
          were_VBD performed_VBN in_IN accordance_NN with_IN the_DT official_JJ guidelines_NNS
          after_IN obtaining_VBG permission_NN of_IN the_DT animal_NN welfare_NN
          committee_NN ._.
        
        
          ATF-BPTI_NNP cloning_VBG
          The_DT plasmid_NN encoding_VBG the_DT ATF-BPTI_NNP (_( pAB_NN )_) was_VBD provided_VBN
          by_IN P_NN ._. Quax_NNP (_( TNO-PG_NNP ,_, Leiden_NNP )_) ._. The_DT ATF_NNP plasmid_NN was_VBD
          constructed_VBN by_IN deleting_VBG the_DT DNA_NNP sequences_NNS encoding_VBG amino_JJ
          acids_NNS 139_CD to_TO 401_CD of_IN the_DT urokinase_NN cDNA_NN plasmid_NN ._. Then_RB a_DT
          DNA_NNP fragment_NN encoding_VBG the_DT amino_JJ acids_NNS residues_NNS 36_CD -_: 96_CD of_IN
          the_DT bovine_JJ pancreatic_JJ trypsin_NN inhibitor_NN (_( BPTI_NNP )_) was_VBD cloned_VBN
          into_IN the_DT ATF_NNP plasmid_NN resulting_VBG in_IN a_DT plasmid_NN encoding_VBG the_DT
          ATF_NNP ,_, the_DT BPTI_NNP and_CC the_DT 11_CD C-_NNP terminal_NN amino_JJ acids_NNS of_IN
          urokinase_NN including_VBG the_DT stop_NN codon_NN ._. After_IN sequence_NN
          confirmation_NN ,_, the_DT ATF-BPTI_NNP cDNA_NN was_VBD cloned_VBN into_IN the_DT
          recombinant_JJ adenovirus_JJ (_( Ad_NN )_) shuttle_NN vector_NN Adapt_NNP ._. The_DT
          murinised_JJ ATF-BPTI_NNP (_( mhAB_NN )_) plasmid_NN was_VBD constructed_VBN by_IN an_DT
          identical_JJ procedure_NN ,_, using_VBG the_DT (_( Tyr_NNP 22_CD ,_, Arg_NNP 27_CD ,_, 29_CD ,_, 30_CD )_) uPA_NN
          mutant_JJ cDNA_NN as_IN starting_VBG sequence_NN [_NN 33_CD ]_NN ._.
        
        
          Adenoviral_NNP vectors_NNS
          Recombinant_NNP adenovirus_JJ vectors_NNS were_VBD generated_VBN in_IN
          PER_NNP ._. C_NNP 6_CD ™_NN cells_NNS by_IN homologous_RB recombination_NN between_IN an_DT
          Adapter_NNP plasmid_NN (_( pAdapt_NN )_) and_CC the_DT E_NNP 1_CD deleted_VBN Ad_NN 5_CD DNA_NNP
          plasmid_NN as_IN described_VBN elsewhere_RB [_NN 34_CD ]_NN ._. The_DT expression_NN
          cassette_NN contains_VBZ a_DT CMV_NNP promoter_NN and_CC SV_NNP 40_CD poly_RB A_DT signal_NN ._.
          As_IN a_DT result_NN of_IN the_DT absence_NN of_IN sequence_NN overlap_VB between_IN
          the_DT Adapt_NNP plasmid_NN and_CC the_DT Ad_NN 5_CD E_NNP 1_CD sequences_NNS integrated_VBN
          into_IN the_DT genome_NN of_IN PER_NNP ._. C_NNP 6_CD ,_, the_DT vector_NN stocks_NNS used_VBN in_IN this_DT
          study_NN does_VBZ not_RB contain_VB replicative_JJ competent_JJ adenovirus_JJ
          (_( RCA_NNP )_) [_NN 35_CD ]_NN ._.
          The_DT Ad_NNP Adapt_NNP mhAB_NN encodes_NNS for_IN a_DT murinised_JJ form_NN of_IN the_DT
          human_JJ ATF-BPTI_NNP [_NN 21_CD ]_NN ._. In_IN this_DT construct_VB the_DT mhAB_NN ,_, is_VBZ
          preceded_VBN by_IN the_DT native_JJ secretion_NN signal_NN peptide_NN of_IN the_DT
          human_JJ urokinase_NN ._. The_DT human_JJ endostatin_NN coding_VBG sequence_NN
          (_( InvivoGen_NNP ,_, CA_NNP ,_, USA_NNP )_) was_VBD cloned_VBN in_IN the_DT Ad_NNP Adapt_NNP shuttle_NN
          vector_NN ._. The_DT encoded_JJ endostatin_NN corresponds_NNS to_TO the_DT 183_CD
          residue_NN of_IN the_DT human_JJ endostatin_NN described_VBN by_IN O_NNP '_POS Reilly_NNP et_CC
          al_NN (_( 1997_CD )_) with_IN an_DT intact_JJ N-_NNP terminus_JJ (_( HSHRDFQ_NNP ._. ._. ._. )_) ,_,
          preceded_VBN by_IN the_DT secretion_NN signal_NN peptide_NN of_IN the_DT human_JJ
          IL-_NNP 2_CD ._. The_DT Ad_NN ._. Adapt_NNP ._. Luc_NNP and_CC the_DT Ad_NN ._. Adapt_NNP ._. LacZ_NNP are_VBP
          recombinant_JJ adenoviral_NN vectors_NNS in_IN which_WDT the_DT E_NNP 3_CD region_NN of_IN
          Ad_NN 5_CD is_VBZ retained_VBN and_CC the_DT gene_NN of_IN interest_NN (_( luciferase_NN or_CC
          LacZ_NNP )_) replaces_VBZ the_DT E_NNP 1_CD region_NN ._. The_DT Ad_NNP Adapt_NNP empty_JJ is_VBZ
          identical_JJ to_TO Ad_NNP Adapt_NNP mhAB_NN except_IN that_IN it_PRP does_VBZ not_RB encode_NN
          any_DT transgene_NN ._.
          All_DT vectors_NNS were_VBD produced_VBN on_IN PER_NNP ._. C_NNP 6_CD ™_NN using_VBG standard_JJ
          procedures_NNS [_NN 35_CD ]_NN ._. Infectious_NNP units_NNS (_( iu_NN )_) were_VBD determined_VBN
          by_IN end_NN point_NN cytopathogenic_JJ effect_NN (_( CPE_NNP )_) assay_NN on_IN 911_CD
          cells_NNS [_NN 36_CD ]_NN ._. Viral_NNP particles_NNS were_VBD determined_VBN by_IN HPLC_NNP [_NN
          37_CD ]_NN ._. The_DT particle_NN to_TO infectious_JJ unit_NN ratio_NN was_VBD always_RB
          lower_JJR than_IN 10_CD ._.
        
        
          Elisa_NNP and_CC activity_NN analysis_NN
          An_DT mhATF-BPTI_JJ ELISA_NNP was_VBD developed_VBN by_IN P_NN ._. Quax_NNP et_CC al_NN [_NN
          21_CD ]_NN ,_, using_VBG a_DT monoclonal_NN antibody_NN specific_JJ for_IN the_DT ATF_NNP
          as_IN the_DT capture_NN antibody_NN and_CC a_DT polyclonal_NN antibody_NN
          directed_VBN against_IN BPTI_NNP as_IN the_DT detector_NN antibody_NN ._. As_IN a_DT
          standard_JJ we_PRP used_VBD urokinase_NN or_CC mhATF-BPTI_JJ ._. The_DT biologic_JJ
          activity_NN of_IN the_DT mhATF-BPTI_JJ was_VBD tested_VBN in_IN vitro_NN in_IN a_DT
          plasmin_NN inhibition_NN assay_NN using_VBG the_DT chromogenic_JJ substrate_NN
          S_NNP 2251_CD (_( Chromogenix_NNP ,_, Mölndahl_NNP ,_, Sweden_NNP )_) ._. Diluted_NNP samples_NNS of_IN
          Ad_NNP Adapt_NNP mhAB_NN infected_VBD A_DT 549_CD cells_NNS medium_NN were_VBD incubated_JJ
          for_IN 15_CD min_NN at_IN room_NN temperature_NN with_IN 200_CD pmol_NN /_NN l_NN plasmin_NN ._.
          S_NNP 251_CD was_VBD then_RB added_VBN and_CC after_IN 24_CD hours_NNS incubation_NN at_IN 37_CD C_NNP
          the_DT A_DT 
          405_CD was_VBD measured_VBN to_TO determine_VB the_DT
          conversion_NN of_IN the_DT chromogenic_JJ substrate_NN ._. Controls_NNP
          consisted_VBD of_IN plasmin_NN solution_NN incubated_JJ with_IN buffer_NN or_CC
          with_IN 1_CD ._. 0_CD KIU_NNP /_NN ml_NN aprotinin_NN ._.
          The_DT human_JJ endostatin_NN activity_NN was_VBD tested_VBN in_IN the_DT human_JJ
          umbilical_JJ vein_NN endothelial_NN cells_NNS HUVEC_NNP proliferation_NN
          assay_NN ._. In_IN short_JJ ,_, HeLa_NNP cells_NNS were_VBD incubated_JJ for_IN 2_CD days_NNS
          with_IN the_DT Ad_NNP Adapt_NNP human_JJ endostatin_NN and_CC the_DT medium_NN was_VBD
          collected_VBN ._. Fibroblast_NNP growth_NN factor_NN (_( bFGF_NN )_) -_: stimulated_VBN
          HUVEC_NNP in_IN 96_CD wells_NNS plate_NN were_VBD incubated_JJ for_IN 2_CD days_NNS with_IN
          hEndostatin_NN infection_NN medium_NN ._. The_DT proliferation_NN of_IN the_DT
          HUVEC_NNP cell_NN was_VBD determined_VBN by_IN measuring_VBG the_DT incorporation_NN
          of_IN BrdU_NNP ._. Levels_NNP of_IN human_JJ endostatin_NN in_IN rat_NN plasma_NN was_VBD
          determined_VBN with_IN a_DT human_JJ enzyme-linked_JJ immunoabsorbent_NN
          assay_NN (_( ELISA_NNP )_) kit_NN (_( InvivoGen_NNP ,_, CA_NNP USA_NNP )_) according_VBG to_TO the_DT
          manufacturers_NNS procedure_NN ._.
        
        
          Tumour_NNP models_NNS
          The_DT L_NNP 42_CD tumour_NN is_VBZ a_DT bronchial_NN squamous_JJ carcinoma_NN that_WDT
          originated_VBN in_IN a_DT Wag_NNP /_NN Rij_NNP rat_NN after_IN intrapulmonary_JJ
          implantation_NN of_IN an_DT iodine-_NN 125_CD seed_NN [_NN 38_CD ]_NN ._. L_NNP 44_CD
          adenocarcinoma_NN was_VBD induced_VBN in_IN Brown_NNP Norway_NNP rats_NNS by_IN local_JJ
          irradiation_NN of_IN the_DT thorax_NN [_NN 39_CD ]_NN ._. Both_DT tumours_NNS are_VBP also_RB
          adapted_VBN to_TO cell_NN culture_NN and_CC give_VB rise_NN to_TO tumours_NNS with_IN the_DT
          same_JJ histological_JJ characteristics_NNS as_IN the_DT original_JJ
          tumours_NNS ._. These_DT two_CD carcinomas_NNS were_VBD serially_RB passaged_JJ in_IN
          syngeneic_JJ rats_NNS for_IN more_JJR than_IN 50_CD passages_NNS ._. The_DT CC_NNP 531_CD
          tumour_NN is_VBZ a_DT dimethylhydrazine-induced_JJ ,_, moderately_RB
          differentiated_JJ colon_NN adenocarcinoma_NN exhibiting_VBG weak_JJ
          immunogenicity_NN [_NN 40_CD ]_NN ._. The_DT tumour_NN is_VBZ transplantable_JJ in_IN
          syngeneic_JJ Wag_NNP /_NN Rij_NNP rats_NNS ._. The_DT subcutaneously_RB growing_VBG tumour_NN
          has_VBZ a_DT low_JJ microvascular_NN density_NN of_IN 1_CD ._. 4_CD %_NN ±_NN 0_CD ._. 6_CD (_( n_NN =_SYM 10_CD )_)
          and_CC a_DT volume_NN doubling_VBG time_NN of_IN 10_CD days_NNS ±_NN 0_CD ._. 8_CD (_( n_NN =_SYM 10_CD )_) ._. For_IN
          the_DT experiments_NNS ,_, the_DT tumours_NNS were_VBD established_VBN in_IN the_DT
          flank_NN of_IN rats_NNS by_IN implanting_VBG small_JJ pieces_NNS (_( 3_CD ×_NN 3_CD ×_NN 3_CD mm_NN )_)
          of_IN tumour_NN tissue_NN sub-cutaneously_JJ as_IN described_VBN before_IN [_NN 41_CD
          ]_NN ._.
          The_DT size_NN of_IN the_DT subcutaneous_JJ tumours_NNS was_VBD measured_VBN in_IN
          three_CD dimensions_NNS at_IN regular_JJ intervals_NNS ,_, using_VBG a_DT Vernier_NNP
          calliper_NN ._. The_DT volume_NN of_IN the_DT tumours_NNS was_VBD calculated_VBN ,_, from_IN
          the_DT three_CD tumour_NN dimensions_NNS measures_NNS (_( a_DT ,_, b_SYM ,_, c_SYM )_) ,_, with_IN the_DT
          formula_NN V_NNP =_SYM πabc_NN /_NN 6_CD ._. The_DT doubling_VBG time_NN of_IN the_DT different_JJ
          tumours_NNS was_VBD calculated_VBN between_IN volume_NN of_IN 1000_CD and_CC 2000_CD mm_NN
          3_CD ._.
          Microvascular_NNP density_NN (_( MVD_NNP )_) in_IN the_DT L_NNP 44_CD ,_, L_NNP 42_CD ,_, and_CC CC_NNP 531_CD
          tumours_NNS was_VBD determined_VBN as_IN follows_VBZ :_: When_WRB the_DT tumours_NNS
          reached_VBD the_DT size_NN of_IN 10_CD ×_NN 10_CD ×_NN 10_CD mm_NN ,_, the_DT animals_NNS were_VBD
          sacrificed_JJ and_CC frozen_VBN sections_NNS through_IN the_DT middle_NN of_IN the_DT
          tumours_NNS were_VBD prepared_VBN ._. We_PRP used_VBD an_DT anti-mouse_JJ CD_NNP 31_CD
          antibody_NN (_( American_NNP Diagnostica_NNP )_) ,_, that_DT cross_NN reacts_VBZ with_IN
          rat_NN CD_NNP 31_CD ,_, to_TO stain_VB specifically_RB the_DT endothelial_NN cells_NNS
          that_WDT can_MD then_RB be_VB easily_RB selected_VBN by_IN the_DT image_NN analyser_NN
          software_NN Qwin_NNP ™_NN ._. The_DT software_NN allowed_VBD us_PRP to_TO quantify_VB the_DT
          surface_NN of_IN the_DT selected_VBN endothelial_NN cells_NNS and_CC to_TO relate_VB
          it_PRP to_TO the_DT surface_NN of_IN non-necrotic_JJ tumour_NN tissue_NN ._. The_DT end_NN
          value_NN is_VBZ the_DT surface_NN of_IN all_DT endothelial_NN cells_NNS as_IN
          percentage_NN of_IN the_DT surface_NN of_IN non-necrotic_JJ tissue_NN :_: the_DT
          microvascular_NN density_NN ._.
          The_DT global_JJ process_NN including_VBG cell_NN infection_NN and_CC
          protein_NN production_NN is_VBZ commonly_RB called_VBN in_IN the_DT literature_NN
          adenoviral_NN permissiveness_NNS ._. The_DT in_IN vitro_NN permissiveness_NNS of_IN
          the_DT different_JJ cell_NN lines_NNS to_TO adenovirus_JJ was_VBD determined_VBN by_IN
          infection_NN of_IN the_DT cells_NNS by_IN graded_JJ MOI_NNP of_IN Ad_NN 5_CD Adapt_NNP
          Luciferase_NNP ._. The_DT Luciferase_NNP activity_NN was_VBD measured_VBN in_IN the_DT
          supernatant_NN of_IN the_DT cell_NN culture_NN lysate_NN after_IN 2_CD days_NNS of_IN
          culture_NN and_CC expressed_VBD in_IN RLU_NNP /_NN milligram_NN of_IN protein_NN ._. The_DT
          in_IN vivo_NN permissiveness_NNS of_IN the_DT tumours_NNS was_VBD assessed_VBN by_IN
          analysing_VBG the_DT lysate_NN of_IN the_DT whole_JJ tumour_NN (_( without_IN any_DT
          surrounding_VBG tissue_NN )_) 2_CD days_NNS after_IN injection_NN of_IN the_DT Ad_NNP
          Adapt_NNP Luc_NNP ._. Adenoviral_NNP vector_NN was_VBD administered_VBN in_IN a_DT volume_NN
          of_IN 100_CD μL_NN to_TO 8_CD ×_NN 8_CD ×_NN 8_CD mm_NN tumours_NNS ._.
          For_IN the_DT metastases_NNS model_NN the_DT L_NNP 44_CD and_CC L_NNP 42_CD cell_NN lines_NNS
          were_VBD cultured_JJ in_IN Dulbecco_NNP 's_POS modified_VBN Eagle_NNP 's_POS medium_NN
          (_( DMEM_NNP )_) supplemented_JJ with_IN 10_CD %_NN FBS_NNP ._. When_WRB the_DT cells_NNS reached_VBD
          80_CD %_NN of_IN confluence_NN ,_, they_PRP were_VBD trypsinised_JJ ,_, washed_VBN and_CC
          resuspended_JJ in_IN PBS_NNP ._. 10_CD 4_CD L_NNP 44_CD tumour_NN cells_NNS or_CC 5_CD ._. 10_CD 4_CD L_NNP 42_CD
          tumour_NN cells_NNS (_( 0_CD ._. 5_LS ml_NN )_) were_VBD injected_VBN into_IN the_DT tail_NN vein_NN of_IN
          the_DT syngeneic_JJ rat_NN ._. The_DT animals_NNS were_VBD sacrificed_JJ after_IN 22_CD
          days_NNS (_( L_NNP 44_CD bearing_NN Brown_NNP Norway_NNP )_) and_CC 53_CD days_NNS (_( L_NNP 42_CD bearing_NN
          Wag_NNP /_NN Rij_NNP )_) ,_, the_DT lungs_NNS fixed_VBN in_IN Bouin_NNP solution_NN and_CC the_DT
          nodules_NNS on_IN the_DT surface_NN were_VBD counted_VBN ._. The_DT first_JJ
          experiments_NNS ,_, in_IN which_WDT animals_NNS were_VBD not_RB treated_VBN ,_, showed_VBD
          that_IN all_DT animals_NNS developed_VBD multiple_JJ metastases_NNS in_IN the_DT
          lungs_NNS ._. The_DT average_JJ number_NN of_IN nodules_NNS counted_VBN on_IN the_DT lung_NN
          surface_NN was_VBD 58_CD in_IN Wag_NNP /_NN Rij_NNP and_CC 93_CD in_IN Brown_NNP Norway_NNP rats_NNS ._.
          The_DT volume_NN doubling_VBG time_NN of_IN the_DT metastases_NNS in_IN the_DT lung_NN
          was_VBD extrapolated_VBN from_IN the_DT volumes_NNS determined_VBN at_IN two_CD time_NN
          points_NNS ._. The_DT volume_NN at_IN 11_CD days_NNS (_( for_IN the_DT L_NNP 44_CD )_) and_CC at_IN 20_CD
          days_NNS (_( for_IN the_DT L_NNP 42_CD )_) was_VBD determined_VBN by_IN measuring_VBG the_DT size_NN
          of_IN microscopic_JJ metastasis_NNS on_IN lung_NN sections_NNS (_( 10_CD metastases_NNS
          per_IN rat_NN ,_, 4_CD rats_NNS per_IN tumour_NN model_NN )_) ._. The_DT final_JJ volume_NN of_IN
          the_DT nodules_NNS on_IN the_DT lung_NN surface_NN was_VBD assessed_VBN ,_, on_IN day_NN 22_CD
          for_IN the_DT L_NNP 44_CD and_CC day_NN 53_CD for_IN the_DT L_NNP 42_CD ,_, using_VBG a_DT Vernier_NNP
          calliper_NN (_( 10_CD nodules_NNS per_IN rat_NN ,_, 10_CD rats_NNS per_IN tumour_NN
          model_NN )_) ._.
        
        
          Luciferase_NNP assays_NNS in_IN tissues_NNS
          Rats_NNP were_VBD sacrificed_JJ by_IN an_DT overdose_NN of_IN isoflurane_NN and_CC
          whole_JJ organs_NNS were_VBD dissected_VBN out_IN ,_, frozen_VBN in_IN liquid_JJ
          nitrogen_NN and_CC stored_VBD at_IN -_: 80_CD °_NN ._. Organs_NNP were_VBD homogenised_JJ in_IN
          phosphate_NN buffered_JJ saline_NN pH_NN 7_CD ._. 8_CD using_VBG a_DT blender_NN ._. To_TO lyse_NN
          the_DT cells_NNS ,_, DTT_NNP (_( SIGMA_NNP ,_, The_DT Netherlands_NNP )_) (_( 1_CD mM_NN )_) and_CC Triton_NNP
          x-_NN 100_CD (_( 0_CD ._. 1_LS %_NN )_) (_( Merck_NNP ,_, The_DT Netherlands_NNP )_) were_VBD added_VBN ._. After_IN
          centrifugation_NN at_IN 10_CD ,_, 000_CD rpm_NN for_IN 10_CD min_NN ,_, 20_CD μl_NN of_IN the_DT
          supernatant_NN was_VBD added_VBN to_TO 100_CD μl_NN of_IN luciferase_NN assay_NN
          substrate_NN (_( Promega_NNP ,_, The_DT Netherlands_NNP )_) ._. Relative_NNP light_JJ
          units_NNS (_( RLU_NNP )_) were_VBD determined_VBN for_IN 30_CD s_VBZ using_VBG a_DT luminometer_NN
          (_( Lumat_NNP 951_CD ,_, Wallac_NNP ,_, Belgium_NNP )_) ._. The_DT amount_NN of_IN protein_NN in_IN
          the_DT extracts_NNS was_VBD determined_VBN using_VBG a_DT commercial_JJ kit_NN
          (_( Bio-_NNP Rad_NNP laboratories_NNS ,_, The_DT Netherlands_NNP )_) based_VBN on_IN the_DT
          Coomasie_NNP brilliant_JJ blue_JJ G_NNP 250_CD binding_JJ assay_NN developed_VBN by_IN
          Bradford_NNP [_NN 42_CD ]_NN ._. The_DT level_NN of_IN luciferase_NN activity_NN in_IN the_DT
          tissue_NN homogenates_NNS was_VBD expressed_VBN in_IN RLU_NNP /_NN mg_NN protein_NN ._. The_DT
          background_NN level_NN of_IN this_DT assay_NN is_VBZ <_NN 1000_CD RLU_NNP /_NN mg_NN protein_NN
          and_CC was_VBD defined_VBN by_IN measuring_VBG luciferase_NN activity_NN in_IN
          organs_NNS of_IN non_NN treated_VBD rats_NNS ._.
        
        
          mhATF-BPTI_JJ determination_NN in_IN tissues_NNS
          Rats_NNP were_VBD sacrificed_JJ by_IN an_DT overdose_NN of_IN isoflurane_NN and_CC
          the_DT blood_NN was_VBD flushed_JJ out_IN by_IN cutting_VBG the_DT vena_NN cava_NN and_CC
          injecting_VBG 100_CD ml_NN PBS_NNP into_IN the_DT right_JJ ventricle_NN ._. The_DT whole_JJ
          organs_NNS or_CC tumours_NNS were_VBD dissected_VBN out_IN and_CC weighted_JJ ,_, frozen_VBN
          in_IN liquid_JJ nitrogen_NN and_CC stored_VBD at_IN -_: 80_CD C_NNP ._. Tissue_NNP and_CC organs_NNS
          were_VBD homogenised_JJ in_IN phosphate_NN buffer_NN pH_NN 7_CD ._. 8_CD using_VBG a_DT
          blender_NN ._. To_TO prepare_VB a_DT cell_NN lysate_NN ,_, DTT_NNP (_( SIGMA_NNP ,_, The_DT
          Netherlands_NNP )_) (_( 1_CD mM_NN )_) and_CC Triton_NNP x-_NN 100_CD (_( 0_CD ._. 1_LS %_NN )_) (_( Merck_NNP ,_, The_DT
          Netherlands_NNP )_) were_VBD added_VBN ._. After_IN centrifugation_NN at_IN 10_CD ,_, 000_CD
          rpm_NN for_IN 10_CD min_NN ,_, the_DT ELISA_NNP was_VBD performed_VBN on_IN 1_CD :_: 100_CD dilution_NN
          of_IN the_DT supernatant_NN ._. Total_JJ protein_NN in_IN the_DT extracts_NNS was_VBD
          determined_VBN as_IN described_VBN above_IN ._. The_DT concentration_NN of_IN
          mhATF-BPTI_JJ was_VBD expressed_VBN in_IN ng_NN /_NN g_SYM tissue_NN ._. The_DT background_NN
          level_NN of_IN this_DT assay_NN is_VBZ <_NN 20_CD ng_NN /_NN g_SYM tissue_NN and_CC was_VBD
          defined_VBN by_IN measuring_VBG the_DT mhATF-BPTI_JJ in_IN organs_NNS of_IN rats_NNS
          treated_VBN with_IN the_DT empty_JJ vector_NN ._.
        
        
          LacZ_NNP expression_NN assay_NN
          Forty-eight_NNP hours_NNS after_IN Ad_NN ._. Adapt_NNP ._. LacZ_NNP administration_NN
          rats_NNS were_VBD sacrificed_JJ and_CC organs_NNS were_VBD removed_VBN and_CC cut_VB in_IN 2_CD
          mm_NN sections_NNS ._. Sections_NNP were_VBD fixed_VBN in_IN 10_CD %_NN phosphate_NN
          buffered_JJ formalin_NN (_( pH_NN 7_CD ._. 0_CD )_) for_IN 60_CD min_NN at_IN room_NN temperature_NN
          and_CC incubated_JJ overnight_JJ in_IN 0_CD ._. 5_CD M_NNP sucrose_NN at_IN 4_CD °_NN C_NNP ._. The_DT
          samples_NNS were_VBD subsequently_RB frozen_VBN in_IN liquid_JJ nitrogen_NN ._. Ten_CD
          micron_NN thick_JJ frozen_VBN sections_NNS were_VBD prepared_VBN and_CC stained_JJ
          with_IN 5_CD -_: bromo-_NN 4_CD -_: chloro-_NN 3_CD -_: indolyl-β-galactopyranoside_JJ
          (_( X-_NNP gal_NN )_) solution_NN (_( Molecular_NNP Probes_NNP ,_, The_DT Netherlands_NNP )_)
          overnight_JJ at_IN 37_CD C_NNP ._. Finally_RB ,_, sections_NNS were_VBD counterstained_JJ
          with_IN Hematoxylin-_NNP Phloxin-_NNP Safran_NNP ._.
        
        
          Statistical_NNP analysis_NN
          Survival_NNP time_NN until_IN tumour_NN size_NN of_IN 20_CD ml_NN was_VBD analysed_JJ
          by_IN log_NN range_NN analysis_NN of_IN Kaplan-_NNP Meier_NNP curves_NNS ._. Analysis_NNP of_IN
          variance_NN (_( ANOVA_NNP )_) was_VBD used_VBN to_TO analyse_NN the_DT differences_NNS in_IN
          tumour_NN growth_NN delay_NN ._. Scheffe_NNP 's_POS test_NN was_VBD employed_VBN to_TO
          analyse_NN the_DT difference_NN between_IN the_DT numbers_NNS of_IN metastases_NNS ,_,
          between_IN plasma_NN concentrations_NNS ,_, and_CC between_IN MVDs_NNP ._.
        
      
      
        Results_NNS
        
          Tumour_NNP characteristics_NNS
          Carcinomas_NNP of_IN the_DT lung_NN were_VBD chosen_VBN ,_, as_IN it_PRP is_VBZ the_DT most_RBS
          frequent_JJ tumour_NN in_IN the_DT cancer_NN population_NN ._. Several_JJ
          vascularisation_NN phenotypes_NNS can_MD be_VB observed_VBN in_IN the_DT
          different_JJ histological_JJ type_NN of_IN lung_NN cancer_NN ._. Therefore_RB a_DT
          bronchial_NN squamous_JJ cell_NN carcinoma_NN and_CC an_DT adenocarcinoma_NN
          with_IN different_JJ microvascular_NN density_NN (_( MVD_NNP )_) were_VBD selected_VBN
          to_TO assess_VB the_DT inhibition_NN effect_NN of_IN the_DT ATF-BPTI_NNP ._. The_DT
          growth_NN characteristics_NNS of_IN the_DT tumours_NNS are_VBP listed_VBN in_IN Table_NNP
          1_CD ._. The_DT L_NNP 44_CD adenocarcinoma_NN grows_VBZ roughly_RB 2_CD ._. 5_CD -_: fold_VB faster_RBR
          than_IN the_DT squamous_JJ cell_NN carcinoma_NN L_NNP 42_CD ._. This_DT difference_NN of_IN
          growth_NN rate_NN holds_VBZ for_IN in_IN vitro_NN culture_NN of_IN the_DT cells_NNS as_RB
          well_RB as_IN for_IN subcutaneous_JJ tumours_NNS and_CC lung_NN metastasis_NNS ._.
          Probably_RB related_VBN to_TO the_DT growth_NN rate_NN ,_, the_DT vascularisation_NN
          of_IN the_DT L_NNP 44_CD tumours_NNS was_VBD significantly_RB higher_JJR (_( p_NN <_NN
          0_CD ._. 001_CD ,_, Scheffe_NNP '_POS test_NN )_) than_IN that_DT of_IN the_DT L_NNP 42_CD tumours_NNS ._. The_DT
          distribution_NN of_IN endothelial_NN cells_NNS in_IN each_DT of_IN the_DT tumour_NN
          is_VBZ homogeneous_JJ in_IN the_DT viable_JJ part_NN of_IN the_DT tumour_NN ._. However_RB ,_,
          the_DT L_NNP 42_CD tumour_NN develops_VBZ a_DT necrotic_JJ area_NN with_IN no_DT vessels_NNS
          in_IN the_DT centre_NN of_IN the_DT tumour_NN mass_NN as_IN it_PRP grows_VBZ above_IN 8_CD ×_NN 8_CD
          ×_NN 8_CD mm_NN ._.
          The_DT in_IN vitro_NN permissiveness_NNS to_TO Ad_NN 5_CD of_IN the_DT cultured_JJ
          cell_NN line_NN showed_VBD that_IN the_DT L_NNP 42_CD carcinoma_NN had_VBD a_DT 2_CD log_NN
          higher_JJR permissiveness_NNS than_IN the_DT L_NNP 44_CD tumour_NN (_( Fig_NNP 1_CD A_DT )_) ._. These_DT
          characteristics_NNS are_VBP preserved_VBN in_IN vivo_NN when_WRB using_VBG the_DT
          luciferase_NN as_RB well_RB as_IN the_DT LacZ_NNP marker_NN gene_NN delivered_VBN in_IN
          10_CD ×_NN 10_CD ×_NN 10_CD mm_NN tumours_NNS ._. Luciferase_NNP activity_NN ,_, 2_CD days_NNS
          after_IN intra_NN tumoral_NN injection_NN of_IN 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP Luc_NNP ,_,
          was_VBD 2_CD log_VB higher_JJR in_IN the_DT L_NNP 42_CD tumours_NNS than_IN in_IN the_DT L_NNP 44_CD
          adenocarcinoma_NN (_( Fig_NNP 1_CD B_NNP )_) ._. The_DT luciferase_NN activity_NN in_IN
          various_JJ organs_NNS of_IN the_DT Wag_NNP /_NN Rij_NNP rats_NNS is_VBZ about_IN the_DT
          background_NN level_NN ,_, and_CC 1_CD to_TO 2_CD log_VB higher_JJR in_IN those_DT of_IN the_DT
          Brown_NNP Norway_NNP rats_NNS ._. Our_PRP$ interpretation_NN is_VBZ that_IN a_DT
          significant_JJ proportion_NN of_IN the_DT vector_NN escapes_NNS into_IN the_DT
          circulation_NN and_CC reaches_VBZ the_DT liver_NN and_CC spleen_NN ,_, because_IN the_DT
          L_NNP 44_CD tumour_NN cells_NNS are_VBP poorly_RB infected_VBN by_IN the_DT adenovirus_JJ ._.
          These_DT observations_NNS were_VBD corroborated_JJ by_IN the_DT results_NNS of_IN
          the_DT intratumoral_NN injection_NN of_IN the_DT β-_NN Galactosidase_NNP
          encoding_VBG adenovirus_JJ ._. Histological_NNP examination_NN ,_, 2_CD days_NNS
          after_IN administration_NN of_IN 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP LacZ_NNP ,_, showed_VBD
          that_IN the_DT L_NNP 42_CD tumour_NN preparations_NNS were_VBD almost_RB completely_RB
          blue_JJ whereas_IN the_DT L_NNP 44_CD tumours_NNS showed_VBD few_JJ blue_JJ cells_NNS around_IN
          the_DT needle_NN track_NN (_( Fig_NNP 2_LS )_) ._. This_DT inhomogeneous_JJ distribution_NN
          is_VBZ not_RB specific_JJ for_IN the_DT L_NNP 44_CD tumour_NN ,_, as_IN it_PRP was_VBD also_RB
          observed_VBN in_IN the_DT L_NNP 42_CD tumours_NNS when_WRB injecting_VBG a_DT lower_JJR dose_NN
          of_IN virus_NN (_( data_NNS not_RB shown_VBN )_) ._.
        
        
          In_IN vitro_NN activity_NN of_IN mhATF-BPTI_JJ and_CC
          hEndostatin_NN
          To_TO assess_VB the_DT functionality_NN of_IN the_DT vectors_NNS ,_, the_DT
          biological_JJ activities_NNS of_IN the_DT encoded_JJ transgenes_NNS were_VBD
          tested_VBN in_IN vitro_NN ._. As_IN depicted_VBN in_IN Fig_NNP 3_CD A_DT ,_, the_DT mhATF-BPTI_JJ
          expressed_VBD in_IN the_DT supernatant_NN of_IN Ad_NNP Adapt_NNP mhAB_NN infected_VBD
          A_DT 459_CD cells_NNS was_VBD able_JJ to_TO inhibit_VB 70_CD %_NN of_IN the_DT plasmin_NN
          activity_NN at_IN a_DT picomolar_NN concentration_NN (_( mol_NN wt_NN :_: 25_CD kD_NN )_) ._.
          Furthermore_RB ,_, mhATF-BPTI_JJ was_VBD shown_VBN to_TO inhibit_VB plasmin_NN
          activity_NN at_IN the_DT cell_NN surface_NN of_IN rat_NN aortic_JJ smooth_JJ muscle_NN
          cells_NNS (_( RASMC_NNP )_) expressing_VBG rat_NN urokinase_NN receptor_NN [_NN 21_CD ]_NN
          ._.
          The_DT biologic_JJ activity_NN of_IN the_DT endostatin_NN encoded_JJ in_IN the_DT
          adenoviral_NN vector_NN was_VBD determined_VBN through_IN the_DT bFGF_NN
          simulated_JJ HUVEC_NNP proliferation_NN assay_NN ._. A_DT linear_JJ dose_NN
          response_NN relationship_NN between_IN endostatin_NN concentration_NN
          and_CC percentage_NN of_IN inhibition_NN of_IN HUVEC_NNP proliferation_NN could_MD
          be_VB demonstrated_VBN (_( Fig_NNP ._. 3_LS B_NNP )_) ._. The_DT ED_NNP 50_CD of_IN endostatin_NN (_( 1000_CD
          ng_NN /_NN ml_NN )_) was_VBD in_IN the_DT range_NN of_IN published_VBN data_NNS [_NN 25_CD ]_NN ._.
          Further_RB ,_, the_DT angiostatic_JJ and_CC antitumoral_NN activities_NNS of_IN
          the_DT human_JJ endostatin_NN has_VBZ been_VBN demonstrated_VBN in_IN different_JJ
          rat_NN models_NNS [_NN 26_CD 27_CD 28_CD ]_NN ._.
        
        
          Secretion_NNP of_IN mhATF-BPTI_JJ and_CC hEndostatin_NN in_IN
          animals_NNS
          Brown_NNP Norway_NNP rats_NNS were_VBD injected_VBN intravenously_RB with_IN
          different_JJ doses_NNS of_IN Ad_NNP Adapt_NNP mhAB_NN (_( from_IN 10_CD 8_CD to_TO 10_CD 10_CD iu_NN )_) and_CC
          the_DT concentration_NN of_IN mhATF-BPTI_JJ was_VBD assessed_VBN in_IN the_DT
          plasma_NN at_IN various_JJ time_NN points_NNS post-infection_JJ ._. The_DT
          detection_NN limits_NNS of_IN the_DT ELISA_NNP in_IN plasma_NN is_VBZ around_IN 5_CD ng_NN /_NN
          ml_NN ._. The_DT results_NNS ,_, depicted_VBN in_IN Fig_NNP 4_CD ,_, show_NN a_DT linear_JJ dose_NN
          response_NN with_IN a_DT maximum_NN level_NN of_IN 500_CD -_: 800_CD ng_NN /_NN ml_NN obtained_VBN
          when_WRB 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP mhAB_NN was_VBD injected_VBN intravenously_RB ._. A_DT
          linear_JJ dose_NN response_NN relationship_NN was_VBD also_RB observed_VBN in_IN
          both_DT rat_NN strains_NNS after_IN iv_NN injection_NN of_IN graded_JJ doses_NNS (_( 10_CD
          9_CD iu_NN to_TO 10_CD 10_CD iu_NN )_) of_IN vectors_NNS encoding_VBG the_DT marker_NN genes_NNS
          luciferase_NN and_CC LacZ_NNP (_( data_NNS not_RB shown_VBN )_) ._. In_IN the_DT Wag_NNP /_NN Rij_NNP rats_NNS
          the_DT plasma_NN levels_NNS of_IN mhATF-BPTI_JJ were_VBD 10_CD times_NNS lower_JJR (_( Fig_NNP ._.
          5_LS A_DT )_) after_IN the_DT same_JJ vector_NN dose_NN ._. The_DT plateau_NN concentration_NN
          after_IN intravenous_JJ injection_NN of_IN 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP mhAB_NN was_VBD
          around_IN 50_CD ng_NN /_NN ml_NN plasma_NN ._. In_IN both_DT rat_NN strains_NNS the_DT plasma_NN
          levels_NNS reached_VBD a_DT plateau_NN after_IN 3_CD days_NNS and_CC remained_VBD
          constant_JJ for_IN at_IN least_JJS 1_CD month_NN ._. The_DT levels_NNS of_IN ATF_NNP in_IN the_DT
          plasma_NN were_VBD similar_JJ to_TO those_DT of_IN the_DT ATF-BPTI_NNP in_IN the_DT Brown_NNP
          Norway_NNP as_RB well_RB as_IN in_IN the_DT Wag_NNP /_NN Rij_NNP rats_NNS (_( Fig_NNP ._. 5_LS B_NNP )_) ._.
          The_DT human_JJ Endostatin_NNP was_VBD measured_VBN in_IN the_DT plasma_NN of_IN
          animals_NNS that_WDT received_VBD 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP hEndostatin_NN
          intravenously_RB (_( Fig_NNP ._. 5_LS C_NNP )_) ._. The_DT concentrations_NNS of_IN endostatin_NN
          were_VBD much_RB higher_JJR than_IN those_DT of_IN mhATF-BPTI_JJ ._. The_DT levels_NNS
          reached_VBD a_DT plateau_NN around_IN 10_CD μg_NN /_NN ml_NN in_IN the_DT Brown_NNP Norway_NNP
          rats_NNS and_CC around_IN 1_CD μg_NN /_NN ml_NN in_IN the_DT Wag_NNP /_NN Rij_NNP rats_NNS ._. Otherwise_RB
          the_DT kinetics_NNS were_VBD roughly_RB similar_JJ to_TO those_DT of_IN mhATF-BPTI_JJ ,_,
          with_IN a_DT plateau_NN lasting_VBG for_IN a_DT month_NN and_CC one_CD log_VB lower_JJR
          levels_NNS in_IN the_DT Wag_NNP /_NN Rij_NNP than_IN in_IN the_DT Brown_NNP Norway_NNP rats_NNS ._.
        
        
          Effects_NNPS of_IN systemic_JJ administration_NN of_IN Ad_NN mhAB_NN on_IN
          tumour_NN growth_NN
          The_DT purpose_NN of_IN these_DT experiments_NNS was_VBD to_TO investigate_VB
          the_DT response_NN to_TO angiostatic_JJ gene_NN therapy_NN of_IN the_DT two_CD
          selected_VBN lung_NN tumours_NNS with_IN different_JJ characteristics_NNS ._.
          Firstly_NNP ,_, we_PRP investigated_VBD the_DT effects_NNS of_IN systemic_JJ delivery_NN
          of_IN mhATF-BPTI_JJ on_IN the_DT growth_NN of_IN subcutaneous_JJ tumour_NN
          implants_NNS ._.
          Brown_NNP Norway_NNP rats_NNS bearing_NN L_NNP 44_CD tumours_NNS were_VBD treated_VBN
          with_IN intravenous_JJ injections_NNS of_IN Ad_NNP Adapt_NNP mhATF-BPTI_JJ daily_NN
          for_IN 4_CD consecutive_JJ days_NNS ._. As_IN depicted_VBN in_IN Fig_NNP 6_CD ,_, three_CD
          different_JJ doses_NNS of_IN vector_NN were_VBD compared_VBN and_CC a_DT significant_JJ
          inhibition_NN of_IN the_DT tumour_NN growth_NN (_( p_NN <_NN 0_CD ._. 001_CD ,_, ANOVA_NNP )_) was_VBD
          observed_VBN with_IN the_DT 2_CD highest_JJS doses_NNS (_( 10_CD 9_CD iu_NN and_CC 2_CD ._. 5_CD 10_CD
          9_CD iu_NN )_) ._. Seven_CD days_NNS after_IN the_DT viral_JJ injection_NN ,_, the_DT plasma_NN
          concentrations_NNS of_IN mhATF-BPTI_JJ were_VBD about_IN 120_CD ng_NN /_NN ml_NN and_CC
          250_CD ng_NN /_NN ml_NN respectively_RB ,_, which_WDT is_VBZ slightly_RB higher_JJR than_IN
          the_DT levels_NNS obtained_VBN after_IN a_DT single_JJ injection_NN ._. In_IN
          contrast_NN ,_, treatment_NN of_IN such_JJ tumours_NNS with_IN a_DT low_JJ dose_NN of_IN
          adenoviral_NN vector_NN (_( 10_CD 8_CD iu_NN )_) ,_, that_WDT induced_VBD lower_JJR plasma_NN
          levels_NNS of_IN mhATF-BPTI_JJ of_IN 10_CD ng_NN /_NN ml_NN ,_, did_VBD not_RB significantly_RB
          inhibit_VB tumour_NN growth_NN ._. Thus_RB it_PRP appears_VBZ that_IN the_DT anti_NN
          tumour_NN activity_NN of_IN mhATF-BPTI_JJ is_VBZ dependant_NN on_IN its_PRP$
          systemic_JJ concentration_NN ._. Higher_JJR doses_NNS could_MD not_RB be_VB
          achieved_VBN without_IN inducing_VBG unacceptable_JJ liver_NN toxicity_NN ,_, as_IN
          manifested_JJ by_IN a_DT severe_JJ inflammatory_JJ infiltrate_VB and_CC
          vacuolisation_NN of_IN the_DT hepatocytes_NNS ._. Therefore_RB 10_CD 10_CD iu_NN was_VBD
          the_DT maximal_NN accepted_VBD dose_NN for_IN these_DT experiments_NNS ._.
          In_IN a_DT second_JJ experiment_NN Ad_NNP Adapt_NNP mhAB_NN and_CC Ad_NNP Adapt_NNP
          hEndostatin_NN were_VBD compared_VBN (_( Fig_NNP ._. 7_CD )_) ._. L_NNP 44_CD tumour_NN pieces_NNS
          were_VBD implanted_VBN subcutaneously_RB on_IN day_NN 0_CD and_CC 10_CD 10_CD iu_NN of_IN
          each_DT vector_NN were_VBD injected_VBN iv_NN in_IN a_DT single_JJ dose_NN on_IN day_NN 20_CD ._.
          The_DT treatment_NN with_IN Ad_NNP Adapt_NNP mhAB_NN caused_VBD a_DT significant_JJ
          inhibition_NN (_( p_NN <_NN 0_CD ._. 0001_CD ,_, ANOVA_NNP )_) of_IN the_DT growth_NN of_IN the_DT
          L_NNP 44_CD tumours_NNS as_IN compared_VBN to_TO the_DT Ad_NNP Adapt_NNP empty_JJ or_CC Ad_NNP Adapt_NNP
          mhATF_NN treated_VBD animals_NNS (_( Fig_NNP ._. 7_CD A_DT )_) ._. The_DT human_JJ endostatin_NN ,_,
          which_WDT plasma_NN level_NN was_VBD around_IN 10_CD μg_NN /_NN ml_NN 2_CD days_NNS after_IN
          vector_NN injection_NN ,_, showed_VBD a_DT slight_JJ but_CC not_RB significant_JJ
          effect_NN (_( p_NN =_SYM 0_CD ._. 007_CD ,_, ANOVA_NNP )_) on_IN tumour_NN growth_NN compared_VBN to_TO
          the_DT empty_JJ vector_NN ._. The_DT mhATF-BPTI_JJ effect_NN was_VBD achieved_VBN with_IN
          a_DT plasma_NN level_NN of_IN mhATF-BPTI_JJ of_IN about_IN 800_CD ng_NN /_NN ml_NN between_IN
          day_NN 5_CD and_CC 30_CD after_IN the_DT virus_NN injection_NN ._. It_PRP is_VBZ required_VBN by_IN
          Dutch_JJ law_NN to_TO sacrifice_VB animals_NNS when_WRB the_DT tumour_NN volume_NN has_VBZ
          surpassed_VBN 20_CD ml_NN ._. That_DT intervention_NN precluded_VBN the_DT
          continuation_NN of_IN the_DT growth_NN curves_NNS after_IN the_DT time_NN point_NN at_IN
          which_WDT the_DT first_JJ animal_NN is_VBZ sacrificed_JJ ._. Therefore_RB the_DT
          animals_NNS with_IN a_DT tumours_NNS volume_NN under_IN 20_CD ml_NN were_VBD plotted_VBD on_IN
          a_DT Kaplan_NNP Meier_NNP analysis_NN graph_NN ._. The_DT result_NN showed_VBD a_DT
          significant_JJ (_( p_NN <_NN 0_CD ,_, 0001_CD ,_, rank_NN test_NN )_) improvement_NN in_IN
          time_NN to_TO sacrifice_VB showing_VBG an_DT Ad_NNP Adapt_NNP mhAB_NN specific_JJ
          protective_JJ effect_NN ._. In_IN the_DT control_NN group_NN ,_, the_DT rats_NNS (_( n_NN =_SYM 9_CD )_)
          reached_VBD the_DT limiting_VBG size_NN after_IN 38_CD to_TO 50_CD days_NNS ,_, whereas_IN in_IN
          the_DT Ad_NNP AB_NNP treated_VBD group_NN (_( n_NN =_SYM 9_CD )_) ,_, the_DT rats_NNS had_VBD tumours_NNS
          above_IN 20_CD ml_NN after_IN 55_CD to_TO 108_CD days_NNS ._. Mean_VB time_NN to_TO sacrifice_VB
          was_VBD prolonged_VBN by_IN 30_CD days_NNS (_( Fig_NNP ._. 7_CD B_NNP )_) ._.
          To_TO complete_VB the_DT study_NN ,_, the_DT same_JJ treatment_NN protocol_NN was_VBD
          applied_VBN to_TO Wag_NNP /_NN Rij_NNP rats_NNS bearing_VBG the_DT slowly_RB growing_VBG and_CC
          poorly_RB vascularised_JJ L_NNP 42_CD adenocarcinoma_NN ._. A_DT single_JJ dose_NN of_IN
          10_CD 10_CD iu_NN of_IN the_DT different_JJ vectors_NNS was_VBD injected_VBN iv_NN on_IN day_NN
          14_CD (_( Fig_NNP ._. 7_CD C_NNP )_) ._. The_DT plateau_NN concentration_NN of_IN mhATF_NN ,_,
          mhATF-BPTI_JJ and_CC endostatin_NN were_VBD low_JJ ,_, around_IN 50_CD ng_NN /_NN ml_NN for_IN
          the_DT 2_CD first_JJ and_CC around_IN 0_CD ._. 5_CD μg_NN /_NN ml_NN for_IN the_DT last_NN
          respectively_RB ._. No_DT significant_JJ inhibition_NN of_IN the_DT tumour_NN
          growth_NN was_VBD observed_VBN in_IN either_DT the_DT mhATF-BPTI_JJ ,_, the_DT mhATF_NN ,_,
          or_CC the_DT endostatin_NN groups_NNS as_IN compared_VBN to_TO the_DT empty_JJ vector_NN
          group_NN ._. We_PRP concluded_VBD that_IN the_DT plasma_NN levels_NNS of_IN our_PRP$
          therapeutic_JJ agents_NNS were_VBD too_RB low_JJ to_TO induce_VB any_DT response_NN in_IN
          this_DT model_NN ._. In_IN an_DT attempt_NN to_TO improve_VB this_DT issue_NN we_PRP
          studied_VBD direct_JJ injection_NN of_IN our_PRP$ vectors_NNS into_IN the_DT
          tumour_NN ._.
        
        
          Intra-tumoral_NNP Ad_NNP Adapt_NNP mhAB_NN administration_NN delays_NNS
          tumour_NN growth_NN in_IN L_NNP 42_CD
          Adenoviral-mediated_NNP delivery_NN of_IN the_DT mhATF-BPTI_JJ
          directly_RB at_IN the_DT tumour_NN site_NN was_VBD studied_VBN in_IN the_DT L_NNP 42_CD lung_NN
          carcinoma_NN implanted_VBN subcutaneously_RB into_IN Wag_NNP /_NN Rij_NNP rats_NNS ._. 19_CD
          days_NNS after_IN implantation_NN ,_, one_CD intratumoral_NN virus_NN injection_NN
          (_( 10_CD 10_CD iu_NN in_IN 0_CD ._. 1_CD ml_NN PBS_NNP )_) per_IN day_NN for_IN 3_CD consecutive_JJ days_NNS
          was_VBD performed_VBN and_CC tumour_NN growth_NN monitored_VBN ._. Seven_CD days_NNS
          after_IN the_DT beginning_NN of_IN the_DT treatment_NN ,_, a_DT significant_JJ (_( p_NN
          <_NN 0_CD ._. 0001_CD ,_, ANOVA_NNP )_) delay_NN of_IN tumour_NN growth_NN was_VBD seen_VBN in_IN
          the_DT Ad_NNP Adapt_NNP mhAB_NN injected_VBD group_NN (_( Fig_NNP ._. 8_CD A_DT )_) ._. The_DT
          mhATF-BPTI_JJ plasma_NN levels_NNS were_VBD under_IN the_DT detection_NN limit_NN
          of_IN the_DT ELISA_NNP ._.
          In_IN contrast_NN ,_, local_JJ delivery_NN of_IN the_DT vector_NN to_TO the_DT very_RB
          low_JJ permissive_JJ L_NNP 44_CD tumour_NN did_VBD not_RB lead_VB to_TO any_DT significant_JJ
          tumour_NN growth_NN inhibition_NN by_IN Ad_NNP Adapt_NNP mhAB_NN (_( Fig_NNP ._. 8_CD B_NNP )_) ._.
        
        
          Local_JJ concentration_NN of_IN mhATF-BPTI_JJ
          The_DT results_NNS of_IN the_DT systemic_JJ administration_NN in_IN the_DT
          Brown_NNP Norway_NNP suggested_VBD a_DT correlation_NN between_IN the_DT plasma_NN
          concentration_NN of_IN mhATF-BPTI_JJ and_CC the_DT tumour_NN response_NN ._. The_DT
          concentrations_NNS of_IN mhATF-BPTI_JJ were_VBD measured_VBN in_IN the_DT plasma_NN
          and_CC in_IN the_DT tumour_NN at_IN 7_CD and_CC 14_CD days_NNS after_IN intravenous_JJ or_CC
          intra-tumoral_JJ injection_NN of_IN the_DT mhATF-BPTI_JJ vector_NN (_( Table_NNP
          2_LS )_) ._. The_DT systemic_JJ delivery_NN of_IN 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP mhAB_NN in_IN L_NNP 44_CD
          bearing_NN Brown_NNP Norway_NNP rats_NNS resulted_VBD in_IN a_DT concentration_NN of_IN
          mhATF-BPTI_JJ in_IN the_DT tumour_NN of_IN about_IN 1_CD ._. 2_CD -_: 1_CD ._. 8_CD μg_NN /_NN g_SYM tumour_NN ._.
          This_DT intra-tumoral_JJ level_NN was_VBD maintained_VBN for_IN at_IN least_JJS 2_CD
          weeks_NNS and_CC is_VBZ 2_CD -_: 3_CD times_NNS higher_JJR than_IN the_DT plasma_NN level_NN ._. This_DT
          suggests_VBZ that_IN mhATF-BPTI_JJ concentrates_VBZ in_IN the_DT tumour_NN ._. The_DT
          concentration_NN of_IN mhATF-BPTI_JJ in_IN the_DT L_NNP 42_CD tumours_NNS after_IN
          intravenous_JJ delivery_NN of_IN the_DT vector_NN was_VBD much_RB lower_JJR around_IN
          150_CD -_: 160_CD ng_NN /_NN g_SYM tumour_NN ,_, but_CC as_IN in_IN the_DT Brown_NNP Norway_NNP rats_NNS
          2_CD -_: 3_CD time_NN higher_JJR than_IN the_DT plasma_NN concentration_NN ._.
          The_DT local_JJ delivery_NN of_IN the_DT transgene_NN in_IN the_DT tumour_NN
          resulted_VBD in_IN a_DT low_JJ concentration_NN of_IN ATF-BPTI_NNP in_IN the_DT L_NNP 44_CD
          tumour_NN (_( 60_CD -_: 90_CD ng_NN /_NN g_SYM tumour_NN )_) and_CC high_JJ concentration_NN in_IN
          the_DT L_NNP 42_CD tumours_NNS (_( 1_CD -_: 1_CD ._. 4_CD μg_NN /_NN g_SYM tumour_NN )_) ._. This_DT was_VBD
          expected_VBN from_IN the_DT 2_CD log_NN higher_JJR permissiveness_NNS to_TO
          adenoviral_NN infection_NN of_IN the_DT L_NNP 42_CD compared_VBN to_TO the_DT L_NNP 44_CD
          tumours_NNS ._.
        
        
          Effect_NN of_IN mhATF-BPTI_JJ on_IN lung_NN metastasis_NNS
          In_IN the_DT subcutaneous_JJ tumour_NN model_NN ,_, the_DT majority_NN of_IN the_DT
          tumour_NN cells_NNS implanted_VBN die_VB ,_, and_CC the_DT surviving_VBG cells_NNS grow_VBP
          in_IN the_DT fibrous_JJ interstitial_NN tissue_NN of_IN the_DT skin_NN ._. The_DT
          subsequent_JJ angiogenesis_NNS give_VBP rise_NN to_TO one_CD small_JJ artery_NN
          that_WDT will_MD vascularise_NN the_DT whole_JJ tumour_NN ._. This_DT probably_RB
          does_VBZ not_RB reflect_VB accurately_RB the_DT clinical_JJ situation_NN ,_, where_WRB
          a_DT primary_JJ carcinoma_NN cell_NN grows_VBZ in_IN a_DT highly_RB vascularised_JJ
          epithelium_NN ._. The_DT angiogenesis_NNS in_IN non-small-cell_JJ lung_NN
          carcinomas_NNS in_IN patients_NNS shows_VBZ four_CD different_JJ patterns_NNS of_IN
          vascularisation_NN :_: basal_NN ,_, diffuse_NN ,_, papillary_JJ and_CC alveolar_NN [_NN
          29_CD ]_NN ._. The_DT basal_NN and_CC the_DT diffuse_NN are_VBP the_DT most_RBS frequent_JJ
          patterns_NNS found_VBD in_IN squamous_JJ carcinomas_NNS and_CC adenocarcinomas_NNS
          respectively_RB ._. Both_DT are_VBP accompanied_VBN by_IN a_DT destruction_NN of_IN
          the_DT normal_JJ lung_NN parenchyma_NN and_CC the_DT production_NN of_IN newly_RB
          formed_VBN vessels_NNS ._. Our_PRP$ lung_NN metastasis_NNS models_NNS in_IN the_DT rat_NN
          also_RB represent_VB these_DT two_CD main_JJ patterns_NNS :_: the_DT L_NNP 44_CD
          (_( adenocarcinoma_NN )_) shows_VBZ a_DT diffuse_NN architecture_NN and_CC the_DT L_NNP 42_CD
          (_( squamous_JJ cell_NN carcinoma_NN )_) grows_VBZ with_IN a_DT basal_NN histological_JJ
          architecture_NN ._. Further_RB characterisation_NN showed_VBD that_IN the_DT
          growth_NN rate_NN of_IN the_DT lung_NN metastases_NNS is_VBZ roughly_RB similar_JJ to_TO
          that_DT of_IN subcutaneous_JJ implants_NNS ,_, the_DT difference_NN between_IN L_NNP 42_CD
          and_CC L_NNP 44_CD being_VBG maintained_VBN at_IN both_DT locations_NNS (_( Table_NNP 1_LS )_) ._.
          The_DT protective_JJ effect_NN of_IN systemic_JJ administration_NN of_IN Ad_NNP
          Adapt_NNP mhAB_NN was_VBD assessed_VBN by_IN treating_VBG the_DT animals_NNS with_IN a_DT
          single_JJ iv_NN dose_NN of_IN Ad_NNP Adapt_NNP mhAB_NN ,_, or_CC Ad_NNP Adapt_NNP hEndostatin_NN ,_,
          or_CC with_IN Ad_NNP Adapt_NNP Empty_JJ as_IN negative_JJ control_NN virus_NN ._. The_DT
          treatment_NN was_VBD administered_VBN when_WRB the_DT micro_JJ metastasis_NNS were_VBD
          a_DT few_JJ hundreds_NNS cells_NNS large_JJ as_IN observed_VBN in_IN not-treated_JJ
          rats_NNS ._. This_DT size_NN was_VBD reached_VBN at_IN 4_CD days_NNS after_IN injection_NN of_IN
          the_DT L_NNP 44_CD tumour_NN cells_NNS and_CC after_IN 13_CD days_NNS in_IN the_DT L_NNP 42_CD model_NN ._.
          The_DT animals_NNS were_VBD sacrificed_JJ when_WRB the_DT lung_NN nodules_NNS were_VBD
          expected_VBN to_TO be_VB 2_CD mm_NN diameter_NN in_IN the_DT control_NN group_NN ._. As_IN
          depicted_VBN in_IN Fig_NNP ._. 9_CD Athe_NNP L_NNP 42_CD metastasis-bearing_JJ rats_NNS
          responded_VBD to_TO treatment_NN with_IN Ad_NNP Adapt_NNP mhAB_NN with_IN a_DT more_JJR
          than_IN 50_CD %_NN reduction_NN in_IN the_DT number_NN of_IN metastases_NNS ._.
          Macroscopic_NNP inspection_NN of_IN the_DT lung_NN surface_NN and_CC
          microscopic_JJ examination_NN of_IN lung_NN sections_NNS gave_VBD similar_JJ
          responses_NNS ._. It_PRP is_VBZ also_RB noteworthy_JJ that_DT treatment_NN with_IN the_DT
          endostatin_NN vector_NN ,_, which_WDT results_VBZ in_IN a_DT much_RB higher_JJR level_NN
          of_IN the_DT angiostatic_JJ protein_NN (_( 1_CD -_: 3_CD μg_NN /_NN ml_NN )_) ,_, does_VBZ not_RB
          significantly_RB reduce_VB the_DT number_NN of_IN metastases_NNS ._. In_IN
          contrast_NN ,_, the_DT L_NNP 44_CD lung_NN metastasis_NNS were_VBD not_RB significantly_RB
          influenced_VBN by_IN either_DT the_DT Ad_NNP Adapt_NNP mhATF-BPTI_JJ or_CC the_DT Ad_NNP
          Adapt_NNP mhATF_NN treatments_NNS (_( Fig_NNP 9_CD B_NNP )_) ._.
          Surprisingly_RB ,_, the_DT systemic_JJ administration_NN of_IN Ad_NNP Adapt_NNP
          mhATF-BPTI_JJ does_VBZ inhibit_VB the_DT growth_NN of_IN L_NNP 42_CD lung_NN
          metastases_NNS ,_, but_CC not_RB of_IN the_DT L_NNP 44_CD metastases_NNS ._. In_IN view_NN of_IN the_DT
          high_JJ permissiveness_NNS of_IN the_DT L_NNP 42_CD tumour_NN cells_NNS ,_, it_PRP seemed_VBD
          possible_JJ that_IN the_DT lung_NN metastases_NNS were_VBD transfected_JJ with_IN
          the_DT mhATF-BPTI_JJ gene_NN ._. Therefore_RB the_DT permissiveness_NNS of_IN the_DT
          lung_NN micrometastasis_NNS was_VBD estimated_VBN ,_, by_IN determining_VBG the_DT
          β-galactosidase_JJ and_CC luciferase_NN activity_NN 2_CD and_CC 7_CD days_NNS
          after_IN the_DT iv_NN injection_NN of_IN 10_CD 10_CD iu_NN Ad_NNP Adapt_NNP LacZ_NNP or_CC Ad_NNP
          Adapt_NNP Luc_NNP into_IN animals_NNS bearing_NN L_NNP 44_CD or_CC L_NNP 42_CD micrometastasis_NNS
          in_IN the_DT lungs_NNS ._. The_DT results_NNS were_VBD however_RB essentially_RB
          negative_JJ ._. The_DT luciferase_NN activity_NN was_VBD under_IN the_DT
          background_NN level_NN in_IN all_DT cases_NNS and_CC the_DT sections_NNS of_IN the_DT
          frozen_VBN lungs_NNS showed_VBD no_DT tumour_NN cell_NN stained_JJ for_IN the_DT
          β-galactosidase_JJ in_IN either_DT L_NNP 44_CD or_CC L_NNP 42_CD metastasis_NNS bearing_NN
          animals_NNS (_( data_NNS not_RB shown_VBN ,_, 6_CD animals_NNS per_IN group_NN )_) ._. Thus_RB ,_, it_PRP
          seems_VBZ that_IN the_DT metastases_NNS are_VBP not_RB actively_RB contributing_VBG
          to_TO the_DT levels_NNS of_IN mhATF-BPTI_JJ in_IN the_DT lungs_NNS and_CC the_DT
          concentration_NN in_IN the_DT metastases_NNS should_MD be_VB similar_JJ to_TO the_DT
          concentration_NN in_IN the_DT lung_NN parenchyma_NN (_( all_PDT the_DT blood_NN being_VBG
          washed_VBN out_IN )_) ._. Therefore_RB ,_, the_DT concentration_NN of_IN mhATF-BPTI_JJ
          in_IN the_DT lung_NN of_IN the_DT two_CD rat_NN strains_NNS was_VBD determined_VBN ._. The_DT
          results_NNS depicted_VBN on_IN Table_NNP 3_CD show_NN that_IN the_DT mhATF-BPTI_JJ
          concentration_NN is_VBZ significantly_RB higher_JJR (_( p_NN <_NN 0_CD ._. 001_CD ,_,
          Scheffe_NNP 's_POS test_NN )_) in_IN the_DT Wag_NNP /_NN Rij_NNP rats_NNS than_IN in_IN the_DT Brown_NNP
          Norway_NNP rats_NNS and_CC is_VBZ not_RB influenced_VBN by_IN the_DT presence_NN of_IN
          metastasis_NNS ._. The_DT Wag_NNP /_NN Rij_NNP rats_NNS concentrate_VBP the_DT mhATF-BPTI_JJ
          in_IN the_DT lung_NN parenchyma_NN about_IN 10_CD fold_VB ,_, reaching_VBG
          therapeutic_JJ levels_NNS ._. In_IN contrast_NN ,_, the_DT same_JJ systemic_JJ
          treatment_NN has_VBZ no_DT effect_NN on_IN the_DT L_NNP 42_CD tumour_NN growing_VBG
          subcutaneously_RB ,_, and_CC this_DT can_MD be_VB explained_VBN by_IN the_DT fact_NN
          that_DT tumour_NN does_VBZ not_RB concentrate_VB the_DT mhATF-BPTI_JJ
          sufficiently_RB ._.
        
        
          Influence_NNP of_IN the_DT tumour_NN mass_NN on_IN the_DT anti_NN tumour_NN
          activity_NN of_IN mhATF-BPTI_JJ
          Radio-_NNP and_CC chemotherapy_NN are_VBP usually_RB expected_VBN to_TO be_VB
          less_RBR effective_JJ on_IN large_JJ tumour_NN mass_NN than_IN on_IN small_JJ
          tumours_NNS ._. In_IN contrast_NN ,_, it_PRP was_VBD shown_VBN that_IN certain_JJ
          anti-angiogenic_JJ compounds_NNS (_( e_SYM ._. g_SYM ._. Combrestatin_NNP )_) act_NN the_DT
          other_JJ way_NN around_IN ,_, namely_RB that_IN they_PRP are_VBP more_RBR active_JJ on_IN
          large_JJ tumours_NNS (_( >_NN 10_CD cm_NN 3_LS )_) than_IN on_IN small_JJ tumours_NNS (_( <_NN 1_CD
          cm_NN 3_LS )_) ._. The_DT supposed_VBN explanation_NN of_IN this_DT peculiar_JJ volume_NN -_:
          response_NN relationship_NN is_VBZ based_VBN on_IN the_DT concept_NN that_IN the_DT
          requirement_NN for_IN new_JJ vessels_NNS increases_NNS with_IN the_DT size_NN of_IN
          the_DT tumour_NN [_NN 30_CD ]_NN ._. Nevertheless_RB ,_, this_DT is_VBZ not_RB a_DT general_JJ
          rule_NN for_IN angiostatics_NNS ._. Various_JJ compounds_NNS such_JJ as_IN
          endostatin_NN ,_, metallo_NN proteinase_NN (_( MMP_NNP )_) inhibitors_NNS ,_, and_CC
          TNP-_NNP 470_CD do_VBP not_RB inhibit_VB the_DT tumour_NN growth_NN when_WRB its_PRP$ size_NN is_VBZ
          too_RB large_JJ ._. Thus_RB ,_, large_JJ tumours_NNS that_WDT are_VBP richly_RB
          vascularised_JJ might_MD be_VB more_RBR sensitive_JJ to_TO angiostatic_JJ
          therapy_NN ._. In_IN order_NN to_TO investigate_VB this_DT issue_NN in_IN the_DT case_NN
          of_IN ATF-BPTI_NNP ,_, two_CD subcutaneous_JJ tumours_NNS with_IN difference_NN
          vascular_NN density_NN were_VBD treated_VBN at_IN different_JJ time_NN points_NNS
          (_( figure_NN 10_CD and_CC 11_CD )_) ._. In_IN the_DT highly_RB vascularised_JJ L_NNP 44_CD as_RB well_RB
          as_IN in_IN the_DT poorly_RB vascularised_JJ CC_NNP 531_CD tumours_NNS ,_, ATF-BPTI_NNP
          could_MD significantly_RB inhibit_VB the_DT growth_NN of_IN the_DT tumours_NNS
          when_WRB they_PRP were_VBD around_IN 100_CD mm_NN 3_CD at_IN the_DT time_NN of_IN treatment_NN ._.
          In_IN contrast_NN ,_, when_WRB the_DT tumours_NNS reached_VBD a_DT volume_NN of_IN 1000_CD
          mm_NN 3_CD ,_, the_DT treatment_NN had_VBD no_DT more_JJR influence_NN on_IN the_DT tumour_NN
          growth_NN ._. The_DT receptor_NN of_IN ATF-BPTI_NNP (_( uPAR_NN )_) is_VBZ known_VBN to_TO be_VB
          principally_RB present_JJ at_IN the_DT outer_JJ edge_NN of_IN the_DT tumour_NN mass_NN
          and_CC as_IN the_DT volume_NN increases_NNS ,_, the_DT proportion_NN of_IN uPAR_NN in_IN
          the_DT tumour_NN will_MD decrease_VB ._. Thus_RB ,_, it_PRP was_VBD expected_VBN that_IN
          large_JJ tumour_NN mass_NN were_VBD insensitive_JJ to_TO the_DT treatment_NN ._. In_IN
          this_DT extent_NN ,_, ATF-BPTI_NNP is_VBZ similar_JJ to_TO the_DT MMPs_NNP inhibitors_NNS ,_,
          in_IN that_DT their_PRP$ best_JJS indication_NN would_MD probably_RB be_VB for_IN
          treatment_NN of_IN residual_JJ disease_NN or_CC small_JJ metastases_NNS ._.
        
      
      
        Discussion_NNP
        Agents_NNS that_WDT inhibit_VBP the_DT growth_NN of_IN new_JJ vessels_NNS in_IN the_DT
        tumours_NNS include_VBP a_DT wide_JJ range_NN of_IN different_JJ compounds_NNS ._. Most_JJS
        of_IN them_PRP are_VBP not_RB toxic_JJ for_IN endothelial_NN cells_NNS ,_, but_CC impair_VB the_DT
        dynamic_JJ process_NN of_IN cell_NN proliferation_NN ,_, migration_NN and_CC matrix_NN
        remodelling_VBG ._. Thus_RB ,_, these_DT agents_NNS are_VBP mostly_RB effective_JJ on_IN the_DT
        formation_NN of_IN new_JJ vessels_NNS and_CC not_RB on_IN the_DT pre-existing_JJ
        vasculature_NN ._. Accordingly_RB such_JJ therapy_NN is_VBZ not_RB expected_VBN to_TO
        cause_VB a_DT dramatic_JJ shrinkage_NN of_IN an_DT established_VBN tumour_NN ._. It_PRP
        appears_VBZ from_IN the_DT different_JJ clinical_JJ trials_NNS with_IN endostatin_NN ,_,
        thalidomide_NN ,_, the_DT synthetic_JJ inhibitors_NNS of_IN MMPs_NNP ,_, and_CC the_DT
        different_JJ anti-_NN VEGFs_NNP that_IN angiostatics_NNS ,_, though_IN slightly_RB
        effective_JJ in_IN advanced_VBD diseases_NNS ,_, are_VBP more_RBR likely_RB indicated_VBD
        in_IN combination_NN with_IN chemotherapy_NN or_CC radiotherapy_NN and_CC as_IN an_DT
        adjuvant_NN therapy_NN to_TO treat_VB small_JJ tumour_NN masses_NNS ,_, in_IN
        particular_JJ local_JJ minimal_JJ residual_JJ disease_NN or_CC
        micrometastasis_NNS ._. In_IN whatever_WDT situation_NN ,_, long_JJ term_NN systemic_JJ
        delivery_NN is_VBZ considered_VBN to_TO be_VB the_DT treatment_NN of_IN choice_NN ._.
        Therefore_RB gene_NN transfer_NN may_MD offer_VB an_DT advantage_NN ._. The_DT
        potential_NN of_IN adenovirus_JJ based_VBN vectors_NNS to_TO infect_NN the_DT liver_NN
        cells_NNS after_IN intravenous_JJ injection_NN makes_VBZ them_PRP suitable_JJ
        vectors_NNS for_IN establishing_VBG a_DT prolonged_JJ systemic_JJ delivery_NN of_IN
        the_DT encoded_JJ protein_NN ._. However_RB ,_, our_PRP$ findings_NNS so_RB far_RB show_VB that_IN
        the_DT achievable_JJ plasma_NN levels_NNS of_IN mhATF-BPTI_JJ are_VBP limited_VBN by_IN
        adenoviral_NN damage_NN to_TO the_DT liver_NN ._. To_TO circumvent_VB this_DT
        limitation_NN ,_, direct_JJ injection_NN of_IN the_DT vector_NN in_IN the_DT tumour_NN
        was_VBD employed_VBN in_IN an_DT attempt_NN to_TO achieve_VB higher_JJR intra_NN tumoral_NN
        levels_NNS of_IN the_DT therapeutic_JJ protein_NN ._.
        High_JJ levels_NNS of_IN mhATF-BPTI_JJ were_VBD achieved_VBN in_IN the_DT
        permissive_JJ L_NNP 42_CD tumour_NN by_IN local_JJ delivery_NN of_IN the_DT vector_NN and_CC
        subsequently_RB a_DT significant_JJ inhibition_NN of_IN tumour_NN growth_NN was_VBD
        obtained_VBN ._. The_DT Wag_NNP /_NN Rij_NNP rat_NN liver_NN is_VBZ poorly_RB permissive_JJ to_TO the_DT
        adenoviral_NN infection_NN and_CC accordingly_RB systemic_JJ
        administration_NN of_IN the_DT vector_NN induces_VBZ low_JJ plasma_NN levels_NNS of_IN
        mhATF-BPTI_JJ (_( <_NN 80_CD ng_NN /_NN ml_NN )_) ._. Consequently_RB ,_, the_DT intra_NN
        tumoral_NN concentration_NN ,_, though_IN 3_CD times_NNS higher_JJR than_IN the_DT
        plasma_NN levels_NNS ,_, was_VBD not_RB high_JJ enough_RB to_TO inhibit_VB its_PRP$ growth_NN ._.
        In_IN contrast_NN ,_, the_DT L_NNP 42_CD lung_NN metastasis_NNS in_IN the_DT Wag_NNP /_NN Rij_NNP did_VBD
        respond_VB to_TO the_DT intravenous_JJ administration_NN of_IN the_DT vector_NN
        encoding_VBG mhATF-BPTI_JJ ,_, though_IN the_DT resulting_VBG plasma_NN level_NN was_VBD
        low_JJ ._. It_PRP was_VBD observed_VBN that_IN the_DT mhATF-BPTI_JJ accumulated_VBN in_IN the_DT
        lung_NN parenchyma_NN ,_, independently_RB of_IN the_DT presence_NN of_IN
        metastasis_NNS ,_, up_IN to_TO a_DT concentration_NN of_IN about_IN 500_CD ng_NN /_NN g_SYM ._. This_DT
        fully_RB explains_VBZ the_DT therapeutic_JJ response_NN observed_VBD in_IN this_DT
        lung_NN metastasis_NNS model_NN ._.
        In_IN contrast_NN ,_, the_DT L_NNP 44_CD adenocarcinoma_NN cells_NNS have_VBP a_DT low_JJ
        permissiveness_NNS to_TO the_DT adenovirus_JJ ._. Consequently_RB ,_, in_IN case_NN of_IN
        direct_JJ intra_NN tumoral_NN delivery_NN of_IN the_DT vector_NN ,_, the_DT tumour_NN
        concentrations_NNS reached_VBN were_VBD low_JJ (_( <_NN 90_CD ng_NN /_NN g_SYM )_) and_CC tumour_NN
        responses_NNS were_VBD not_RB observed_VBN ._. However_RB ,_, the_DT Brown_NNP Norway_NNP rat_NN
        liver_NN is_VBZ 10_CD times_NNS more_RBR permissive_JJ to_TO the_DT adenovirus_JJ and_CC
        produced_VBN high_JJ levels_NNS of_IN the_DT vector-encoded_JJ protein_NN ._.
        Additionally_RB ,_, the_DT tumour_NN tissue_NN concentrates_VBZ 2_CD to_TO 3_CD fold_VB
        the_DT mhATF-BPTI_JJ from_IN the_DT plasma_NN ,_, resulting_VBG in_IN high_JJ intra_NN
        tumoral_NN levels_NNS ._. Using_VBG graded_JJ doses_NNS of_IN Ad_NNP Adapt_NNP mhAB_NN ,_, a_DT
        linear_JJ relation_NN was_VBD observed_VBN between_IN the_DT dose_NN and_CC the_DT
        plasma_NN level_NN as_RB well_RB as_IN between_IN the_DT dose_NN and_CC the_DT tumour_NN
        growth_NN delay_NN ._. It_PRP appeared_VBD that_IN a_DT significant_JJ tumour_NN
        response_NN could_MD be_VB obtained_VBN when_WRB the_DT intra_NN tumoral_NN
        concentration_NN of_IN mhATF-BPTI_JJ was_VBD above_IN 400_CD ng_NN /_NN g_SYM of_IN tissue_NN ._.
        In_IN contrast_NN ,_, at_IN the_DT same_JJ plasma_NN levels_NNS that_WDT inhibited_VBD the_DT
        growth_NN of_IN the_DT subcutaneous_JJ L_NNP 44_CD could_MD not_RB induce_VB any_DT
        response_NN on_IN the_DT metastasis_NNS in_IN the_DT lungs_NNS ._. The_DT tissue_NN
        concentration_NN of_IN mhATF-BPTI_JJ in_IN the_DT lung_NN of_IN the_DT Brown_NNP Norway_NNP
        rats_NNS was_VBD apparently_RB too_RB low_JJ (_( <_NN 180_CD ng_NN /_NN g_SYM )_) for_IN eliciting_VBG
        a_DT decrease_NN in_IN the_DT number_NN of_IN metastasis_NNS ._.
      
      
        Conclusion_NNP
        The_DT tumour_NN growth_NN inhibition_NN in_IN both_DT poorly_RB and_CC highly_RB
        vascularised_JJ L_NNP 44_CD and_CC L_NNP 42_CD tumours_NNS was_VBD achieved_VBN only_RB when_WRB the_DT
        concentration_NN of_IN mhATF-BPTI_JJ in_IN the_DT tumoral_NN mass_NN or_CC in_IN the_DT
        surrounding_VBG tissue_NN reached_VBD a_DT value_NN of_IN at_IN least_JJS 300_CD to_TO 400_CD
        ng_NN /_NN g_SYM ._. In_IN contrast_NN ,_, mhATF_NN and_CC the_DT human_JJ endostatin_NN even_RB at_IN
        higher_JJR molecular_JJ plasma_NN concentration_NN than_IN the_DT mhATF-BPTI_JJ
        did_VBD not_RB achieve_VB any_DT significant_JJ inhibition_NN of_IN tumour_NN growth_NN
        as_IN in_IN established_VBN subcutaneous_JJ tumours_NNS as_RB well_RB as_IN in_IN
        micrometastasis_NNS in_IN the_DT lungs_NNS ._. Other_JJ investigators_NNS reported_VBD
        that_IN at_IN those_DT concentrations_NNS endostatin_NN and_CC ATF_NNP induced_VBD
        responses_NNS of_IN tumours_NNS and_CC metastases_NNS in_IN mice_NNS [_NN 31_CD 32_CD ]_NN ._. The_DT
        absence_NN of_IN a_DT response_NN in_IN our_PRP$ tumour_NN model_NN might_MD be_VB due_JJ to_TO a_DT
        lower_JJR sensitivity_NN to_TO angiostatic_JJ agents_NNS ._. In_IN that_DT case_NN our_PRP$
        results_NNS suggest_VBP that_IN ATF-BPTI_NNP is_VBZ a_DT more_RBR potent_JJ agent_NN than_IN
        endostatin_NN or_CC ATF_NNP ._.
      
      
        List_NN of_IN abbreviations_NNS
        ATF_NNP :_: Amino_NNP Terminal_NNP Fragment_NNP
        bFGF_NN :_: Fibrobast_NNP Growth_NNP Factor_NN b_SYM
        BPTI_NNP :_: Bovine_NNP Pancreatic_NNP Trypsin_NNP Inhibitor_NNP
        GPI_NNP :_: Glycophosphatidylinositol_NNP
        HUVEC_NNP :_: Human_NNP Umbilical_NNP Vein_NNP Endothelial_NNP Cell_NNP
        KIU_NNP :_: Kallikrein_NNP Inhibition_NNP Unit_NNP
        MDV_NNP :_: Micro-_NNP Vascular_NNP Density_NNP
        mhATF_NN :_: Murinised_NNP human_JJ ATF_NNP
        mhATF-BPTI_JJ :_: Murinised_NNP human_JJ ATF-BPTI_NNP
        MMP_NNP :_: Matrix_NNP Metallo-_NNP Proteinase_NNP
        TIMP_NNP :_: Tissue_NNP Inhibitor_NNP of_IN Metallo_NNP Protease_NNP
        uPA_NN :_: Urokinase_NNP Plasminogen_NNP Activator_NNP
        uPAR_NN :_: Urokinase_NNP Receptor_NNP
        VEGF_NNP :_: Vascular_NNP Endothelial_NNP Growth_NNP Factor_NN
      
      
        Competing_VBG interests_NNS
        None_NN declared_VBD ._.
      
      
        Authors_NNP '_'' Contributions_NNP
        PL_NNP and_CC JA_NNP participated_VBD in_IN the_DT all_DT aspects_NNS of_IN the_DT study_NN
        and_CC DvB_NNP is_VBZ the_DT principal_JJ investigator_NN ._.
      
    
  
